These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

464 related items for PubMed ID: 16621179

  • 21. Mononuclear cells from patients recovered from cutaneous leishmaniasis respond to Leishmania major amastigote class I nuclease with a predominant Th1-like response.
    Farajnia S, Mahboudi F, Ajdari S, Reiner NE, Kariminia A, Alimohammadian MH.
    Clin Exp Immunol; 2005 Mar; 139(3):498-505. PubMed ID: 15730396
    [Abstract] [Full Text] [Related]

  • 22. Successful vaccination against Leishmania chagasi infection in BALB/c mice with freeze-thawed Leishmania antigen and Corynebacterium parvum.
    Vilela Mde C, Gomes DC, Marques-da-Silva Ede A, Serafim TD, Afonso LC, Rezende SA.
    Acta Trop; 2007 Mar; 104(2-3):133-9. PubMed ID: 17919443
    [Abstract] [Full Text] [Related]

  • 23. Vaccination against cutaneous leishmaniasis in a murine model. I. Induction of protective immunity with a soluble extract of promastigotes.
    Scott P, Pearce E, Natovitz P, Sher A.
    J Immunol; 1987 Jul 01; 139(1):221-7. PubMed ID: 3495599
    [Abstract] [Full Text] [Related]

  • 24. Immunostimulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen.
    Tewary P, Sukumaran B, Saxena S, Madhubala R.
    Vaccine; 2004 Aug 13; 22(23-24):3053-60. PubMed ID: 15297055
    [Abstract] [Full Text] [Related]

  • 25. Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients.
    Rafati S, Gholami E, Hassani N, Ghaemimanesh F, Taslimi Y, Taheri T, Soong L.
    Vaccine; 2007 May 22; 25(21):4159-69. PubMed ID: 17395340
    [Abstract] [Full Text] [Related]

  • 26. Protective immune responses induced by vaccination with an expression genomic library of Leishmania major.
    Piedrafita D, Xu D, Hunter D, Harrison RA, Liew FY.
    J Immunol; 1999 Aug 01; 163(3):1467-72. PubMed ID: 10415048
    [Abstract] [Full Text] [Related]

  • 27. DNA based vaccination with a cocktail of plasmids encoding immunodominant Leishmania (Leishmania) major antigens confers full protection in BALB/c mice.
    Ahmed SB, Touihri L, Chtourou Y, Dellagi K, Bahloul C.
    Vaccine; 2009 Jan 01; 27(1):99-106. PubMed ID: 18951941
    [Abstract] [Full Text] [Related]

  • 28. Cysteine proteinase type III is protective against Leishmania infantum infection in BALB/c mice and highly antigenic in visceral leishmaniasis individuals.
    Khoshgoo N, Zahedifard F, Azizi H, Taslimi Y, Alonso MJ, Rafati S.
    Vaccine; 2008 Oct 29; 26(46):5822-9. PubMed ID: 18804512
    [Abstract] [Full Text] [Related]

  • 29. Experimental Leishmania (L.) amazonensis leishmaniasis: characterization and immunogenicity of subcellular fractions.
    do Valle TZ, Gaspar EB, Souza-Lemos C, Souza CS, Márquez FB, Baetas-da-Cruz W, d'Escofier LN, Côrte-Real S, Calabrese KS, da Costa SC.
    Immunol Invest; 2007 Oct 29; 36(4):473-92. PubMed ID: 17691027
    [Abstract] [Full Text] [Related]

  • 30. Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections.
    Zanin FH, Coelho EA, Tavares CA, Marques-da-Silva EA, Silva Costa MM, Rezende SA, Gazzinelli RT, Fernandes AP.
    Microbes Infect; 2007 Jul 29; 9(9):1070-7. PubMed ID: 17644455
    [Abstract] [Full Text] [Related]

  • 31. Potential of KM+ lectin in immunization against Leishmania amazonensis infection.
    Teixeira CR, Cavassani KA, Gomes RB, Teixeira MJ, Roque-Barreira MC, Cavada BS, da Silva JS, Barral A, Barral-Netto M.
    Vaccine; 2006 Apr 05; 24(15):3001-8. PubMed ID: 16455170
    [Abstract] [Full Text] [Related]

  • 32. Interferon-gamma-inducing oral vaccination with Leishmania amazonensis antigens protects BALB/c and C57BL/6 mice against cutaneous leishmaniasis.
    Pinto EF, de Mello Cortezia M, Rossi-Bergmann B.
    Vaccine; 2003 Sep 08; 21(25-26):3534-41. PubMed ID: 12922080
    [Abstract] [Full Text] [Related]

  • 33. Studies on the protective efficacy and immunogenicity of Hsp70 and Hsp83 based vaccine formulations in Leishmania donovani infected BALB/c mice.
    Kaur J, Kaur T, Kaur S.
    Acta Trop; 2011 Jul 08; 119(1):50-6. PubMed ID: 21530477
    [Abstract] [Full Text] [Related]

  • 34. Leishmania major: immune response in BALB/c mice immunized with stress-inducible protein 1 encapsulated in liposomes.
    Badiee A, Jaafari MR, Khamesipour A.
    Exp Parasitol; 2007 Feb 08; 115(2):127-34. PubMed ID: 16979165
    [Abstract] [Full Text] [Related]

  • 35. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection.
    Gurunathan S, Prussin C, Sacks DL, Seder RA.
    Nat Med; 1998 Dec 08; 4(12):1409-15. PubMed ID: 9846579
    [Abstract] [Full Text] [Related]

  • 36. Total Leishmania antigens with Poly(I:C) induce Th1 protective response.
    Sanchez MV, Eliçabe RJ, Di Genaro MS, Germanó MJ, Gea S, García Bustos MF, Salomón MC, Scodeller EA, Cargnelutti DE.
    Parasite Immunol; 2017 Nov 08; 39(11):. PubMed ID: 28901553
    [Abstract] [Full Text] [Related]

  • 37. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major.
    Gurunathan S, Sacks DL, Brown DR, Reiner SL, Charest H, Glaichenhaus N, Seder RA.
    J Exp Med; 1997 Oct 06; 186(7):1137-47. PubMed ID: 9314562
    [Abstract] [Full Text] [Related]

  • 38. Leishmanial amastigote antigen P-2 induces major histocompatibility complex class II-dependent natural killer-cell reactivity in cells from healthy donors.
    Nylén S, Maasho K, McMahon-Pratt D, Akuffo H.
    Scand J Immunol; 2004 Mar 06; 59(3):294-304. PubMed ID: 15030581
    [Abstract] [Full Text] [Related]

  • 39. Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1 response.
    Bhowmick S, Ravindran R, Ali N.
    Vaccine; 2007 Aug 29; 25(35):6544-56. PubMed ID: 17655984
    [Abstract] [Full Text] [Related]

  • 40. Fragments of antigen-loaded dendritic cells (DC) and DC-derived exosomes induce protective immunity against Leishmania major.
    Schnitzer JK, Berzel S, Fajardo-Moser M, Remer KA, Moll H.
    Vaccine; 2010 Aug 16; 28(36):5785-93. PubMed ID: 20615489
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.